Latest Omeprazole Stories

Baclofen, esomeprazole investigated as treatmentsThe impact of upper GI conditions, like gastroesophageal reflux disease (GERD) and functional dyspepsia, on sleep"”and treatments aimed at providing relief to heartburn/acid reflux patients who suffer from disordered sleep"”were explored in three new studies related to sleep dysfunction presented today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.Functional dyspepsia is a common,...

ALLEGAN, Mich., Sept. 24 /PRNewswire-FirstCall/ -- Perrigo Company (Nasdaq: PRGO; TASE) announced that it has filed with the U.S. Food and Drug Administration (FDA) an Abbreviated New Drug Application (ANDA) for omeprazole 20mg/sodium bicarbonate 1100mg, the generic equivalent of Zegerid OTC(TM), and that it provided prior notice of this filing to Schering-Plough HealthCare Products, Inc. a subsidiary of Merck & Co., Inc., the owner of the brand regulatory approval and the Curators of...

PARIS, July 27 /PRNewswire-FirstCall/ -- Medco Research Institute(TM), LLC, a wholly owned subsidiary of Medco Health Solutions, Inc. (NYSE: MHS), is sponsoring a study to determine the optimal antiplatelet treatment for patients who are also using a proton pump inhibitor (PPI), a commonly prescribed category of heartburn medications. The study will examine the impact that the PPI, Prevacid® (lansoprazole), has on the effect of two different anti-platelet agents, Effient (prasugrel) and...

WOODCLIFF LAKE, N.J., July 1 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that it began shipping the 20mg/1100mg and 40mg/1100mg strengths of omeprazole and sodium bicarbonate capsules to the trade. Omeprazole and sodium bicarbonate capsules are the generic version of Santarus' Zegerid®. Annual U.S. sales of Zegerid capsules are approximately $195 million, according to IMS Health data. Par has been awarded 180 days of marketing exclusivity for...

CINCINNATI, July 1 /PRNewswire/ -- Prasco Laboratories announced today that it is now shipping the authorized generic version of ZEGERID® (omeprazole/sodium bicarbonate) capsules. Authorized generics are generic pharmaceuticals manufactured identically to the brand product and sold under a private label. Under the terms of a distribution and supply agreement with Santarus, Prasco will sell and distribute the capsule form of Omeprazole/Sodium Bicarbonate in 20 mg and 40 mg strengths in...

NEW YORK, June 17 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) announced that new data, published today by The Lancet, show that arthritis patients at increased gastrointestinal (GI) risk taking CELEBREX demonstrated a significantly lower incidence of the novel composite endpoint of clinically significant upper and lower GI events compared with patients taking diclofenac plus omeprazole. This difference was driven by clinically significant decreases in hemoglobin and/or hematocrit of...

Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk. (Logo:...

WOODCLIFF LAKE, N.J., April 15 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of the University of Missouri's patents relating to omeprazole/sodium bicarbonate capsules (20 mg/1.1 g and 40 mg/1.1 g) and powders for oral suspension (20 mg/1.68 g and 40 mg/1.68 g), which are listed in the Orange Book for Santarus's Zegerid® product. Par earlier...

New research by the University of East Anglia (UEA) shows no risk in combining two commonly-prescribed treatments for patients at risk of heart attacks and strokes.Published this month in the journal Alimentary Pharmacology & Therapeutics, the study is the largest investigation yet into concerns of an adverse interaction between Proton Pump Inhibitors (PPIs) and the antiplatelet drug clopidogrel.The researchers analyzed data from 23 large randomized clinical trials involving more than...

WHITEHOUSE STATION, N.J., April 1 /PRNewswire/ -- Merck & Co., Inc. announced that beginning today, ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules), a new over-the-counter (OTC) option for treating frequent heartburn without a prescription, will become available in drug stores, grocery stores, mass merchandisers and club stores nationwide. The only OTC proton pump inhibitor (PPI) product with two active ingredients, ZEGERID OTC delivers relief in a different way....